TARS FY 2024 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$183M+948.6% YoY

Gross Profit

$170M93.0% margin

Operating Income

-$121M-65.9% margin

Net Income

-$116M-63.2% margin

EPS (Diluted)

$-3.07

Cash Flow

Operating Cash Flow

-$83M

Free Cash Flow

-$85M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$377M

Total Liabilities

$152M

Stockholders' Equity

$225M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$183M	$17M	+948.6%
Gross Profit	$170M	$16M	+973.1%
Operating Income	-$121M	-$143M	+15.8%
Net Income	-$116M	-$136M	+15.0%